The global renal insufficiency treatment market garnered a market value of US$ 12 Billion in 2022 and is expected to accumulate a market value of US$ 35.28 Billion by registering a CAGR of 10.3% in the forecast period 2023 to 2033. Growth of the renal insufficiency treatment market can be attributed to increasing number of patients with chronic kidney disease, the rising adoption of advanced dialysis techniques, and the development of new and more effective medications for the treatment of renal insufficiency. The market for renal insufficiency treatment registered a CAGR of 5.8% in the historical period 2018 to 2022
Renal insufficiency, also known as chronic kidney disease, is a condition in which the kidneys are not functioning properly. Treatment for renal insufficiency typically focuses on managing the underlying cause of the disease and preventing further damage to the kidneys.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 13.24 Billion |
| Anticipated Forecast Value (2033) | US$ 35.28 Billion |
| Projected Growth Rate (2023 to 2033) | 10.3% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Renal insufficiency treatment reflected a value of 5.8% during the historical period, 2018 to 2022.
Increasing prevalence of chronic kidney disease, the rising adoption of home-based dialysis treatments, and the introduction of new and more effective drugs for the treatment of renal insufficiency contributed to the growth of the market in the historical period. Additionally, the COVID-19 pandemic in 2020 and 2021 had a significant impact on the market, with disruptions to supply chains and a decrease in patient visits to healthcare facilities.
Overall, the renal insufficiency treatment market is expected to be driven by a combination of increasing demand for treatment and ongoing innovation in the development of new therapies and treatment options.
Thus, the market for Renal insufficiency treatment is expected to register a CAGR of 10.3% in the forecast period 2023 to 2033.
Increasing prevalence of chronic kidney disease favoring the growth of market
The increasing prevalence of chronic kidney disease is one of the primary drivers of the renal insufficiency treatment market. According to the National Kidney Foundation, about 37 Billion people in the United States alone have chronic kidney disease. This high prevalence is driving demand for treatments and therapies to manage the condition.
Advancements in dialysis technology, such as the development of home-based and portable dialysis machines, are expanding access to treatment for renal insufficiency patients. These advancements are making it easier for patients to receive dialysis in a variety of settings, including their homes, which is improving their quality of life.
The development of new medications for the treatment of renal insufficiency is another driver of the market. Many pharmaceutical companies are investing in research and development to create new therapies that can slow the progression of chronic kidney disease and reduce the risk of complications.
The aging population is also a driver of the renal insufficiency treatment market, as the risk of chronic kidney disease increases with age. As the population continues to age, the demand for treatments and therapies to manage renal insufficiency is expected to increase.
Increasing awareness and education about chronic kidney disease and the importance of early detection and management is also driving the market. As more people become aware of the risks associated with chronic kidney disease, they are more likely to seek treatment and take steps to manage the condition.
Availability of treatments shaping landscape for renal insufficiency treatment market
Medications: Medications can be used to control high blood pressure, reduce proteinuria (excess protein in the urine), manage anemia, and lower cholesterol levels. Some medications can also slow the progression of chronic kidney disease.
Dietary changes: Dietary changes may include reducing the intake of sodium, potassium, and phosphorus, as well as increasing the intake of protein and calories. These changes can help manage symptoms and slow the progression of the disease.
Dialysis: Dialysis is a procedure that filters waste and excess fluids from the blood when the kidneys are not functioning properly. There are two main types of dialysis: hemodialysis and peritoneal dialysis.
Kidney transplant: A kidney transplant involves receiving a healthy kidney from a donor, which can restore normal kidney function. This is usually considered when other treatments are no longer effective.
Management of underlying conditions: Treating underlying conditions that contribute to chronic kidney disease, such as diabetes or high blood pressure, can also help manage the disease and prevent further damage to the kidneys.
Principal Consultant
Limited healthcare resources and expensive nature of treatment derailing growth of renal insufficiency market
The cost of renal insufficiency treatment is high, and it can be a significant burden for patients and healthcare systems. Dialysis and kidney transplant can be expensive, and medications used to manage chronic kidney disease can also be costly.
In some regions, healthcare resources are limited, and access to treatment for renal insufficiency may be difficult. This can be due to a lack of medical facilities, trained healthcare professionals, or funding. Adherence to treatment can be a challenge for patients with chronic kidney disease. Treatment often involves significant lifestyle changes, such as dietary modifications and regular medical appointments, which can be difficult for patients to manage over the long term.
Underdiagnosis and late detection of chronic kidney disease can lead to delayed treatment and poorer outcomes. Lack of awareness and routine screening for chronic kidney disease may contribute to underdiagnosis.
Treatment for renal insufficiency can sometimes have significant side effects, which can be a challenge for patients to manage. For example, dialysis can cause fatigue, nausea, and muscle cramps, while some medications can cause gastrointestinal upset or skin rashes.
Advancements in treatment options propelling the treatment options for renal insufficiency
The North America renal insufficiency treatment market is one of the largest in the world, with the United States and Canada being the major contributors. The market is driven by factors such as the high prevalence of chronic kidney disease (CKD), advancements in dialysis technology, and the increasing awareness about kidney diseases and their management.
The United States is the largest market for renal insufficiency treatment in North America, with a high prevalence of CKD and a large aging population. According to the National Kidney Foundation, more than 37 Billion Americans have CKD, and the disease is the ninth leading cause of death in the country. The availability of advanced dialysis technology, such as home-based and portable dialysis machines, is also contributing to the growth of the market.
Canada is another significant market for renal insufficiency treatment in North America. The country has a universal healthcare system that provides coverage for dialysis and kidney transplant, which has led to high rates of treatment for CKD patients. The Canadian Society of Nephrology reports that there are more than 23,000 patients on dialysis in Canada, and more than 3,000 kidney transplants have been performed in the country since 2008.
Overall, the North America renal insufficiency treatment market is expected to continue to grow in the coming years, driven by factors such as the increasing prevalence of CKD, advancements in treatment options, and growing awareness about kidney disease management. Thus, North America is expected to possess 48% market share for renal insufficiency in 2023.
Aging population contributing to market growth for renal insufficiency in Europe
The Europe renal insufficiency treatment market is a significant contributor to the global renal insufficiency treatment market. The market is driven by factors such as the increasing prevalence of chronic kidney disease (CKD), the availability of advanced treatment options, and the growing awareness about kidney disease management.
The United Kingdom, Germany, and France are some of the major markets for renal insufficiency treatment in Europe. The high prevalence of CKD and the availability of advanced treatment options, such as home-based and portable dialysis machines, are contributing to the growth of the market in these countries.
The United Kingdom has a high prevalence of CKD, with more than three Billion people in the country suffering from the disease, according to the National Kidney Federation. The country also has a well-established healthcare system that provides coverage for dialysis and kidney transplant, which has led to high rates of treatment for CKD patients.
Germany is another significant market for renal insufficiency treatment in Europe. The country has a large aging population, which is contributing to the growth of the market. The availability of advanced dialysis technology, such as high-flux dialysis and hemodiafiltration, is also contributing to the growth of the market in Germany.
France is also a major market for renal insufficiency treatment in Europe. The country has a high prevalence of CKD, with more than three Billion people in the country suffering from the disease, according to the French Society of Nephrology. The country also has a well-established healthcare system that provides coverage for dialysis and kidney transplant. Thus, Europe is expected to possess 41% market share for renal insufficiency in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Advanced dialysis technology making dialysis process easier for patients in renal insufficiency treatment
Dialysis centres can be a good option for renal insufficiency treatment, particularly for patients with end-stage renal disease (ESRD) who require regular dialysis treatment. Dialysis centres are specialized facilities designed specifically to provide dialysis treatment to patients with kidney failure.
Dialysis treatment involves removing waste and excess fluid from the blood when the kidneys are no longer able to do so on their own. This treatment can help manage the symptoms of kidney failure and improve the patient's quality of life.
Dialysis centres offer patients access to specialized medical care and support from a team of healthcare professionals, including nephrologists, nurses, and dialysis technicians. These centres are equipped with advanced dialysis technology and are staffed by trained healthcare professionals who can monitor patients closely and adjust their treatment as needed. Thus, dialysis centres are expected to possess 45% market share for renal insufficiency treatment market in 2023.
Key players in the renal insufficiency treatment are Nipro Corp., Fresenius Medical Care AG & Co. KGaA, Baxter International, Inc., Medtronic Plc, Braun Melsungen AG, Asahi Kasei Medical Co., Ltd., Cantel Medical, Nikkiso Co., Ltd., JMS Co. Ltd., AstraZeneca
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 13.24 Billion |
| Market Value in 2033 | US$ 35.28 Billion |
| Growth Rate | CAGR of 10.3% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
From 2018 to 2022, the Renal insufficiency treatment market grew at a CAGR of 5.8%
The global Renal insufficiency treatment market is expected to grow with a 10.3% CAGR during 2023 to 2033.
As of 2033, the Renal insufficiency treatment market is expected to reach US$ 35.28 Billion
Dialysis centres are expected to hold 45% of the market share in 2023 for Renal insufficiency treatment market.
North America is expected to possess 48% market share for Renal insufficiency treatment market in 2023.
Europe Renal insufficiency treatment market size is expected to possess 41% market share in 2023.
1. Executive Summary | Renal Insufficiency Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
5.3.1. Dialysis
5.3.2. Medication
5.3.3. Kidney Transplantation
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Dialysis Centres
6.3.2. Hospital & Clinics
6.3.3. Research & Academic Institutes
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia
7.3.5. East Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Treatment Type
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment Type
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment Type
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment Type
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment Type
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By End User
10.4. Key Takeaways
11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Rest of South Asia
11.2.2. By Treatment Type
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By End User
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Treatment Type
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By End User
12.4. Key Takeaways
13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Treatment Type
13.2.3. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By End User
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Treatment Type
14.2.3. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment Type
14.3.3. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment Type
15.1.2.2. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment Type
15.2.2.2. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment Type
15.3.2.2. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment Type
15.4.2.2. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment Type
15.5.2.2. By End User
15.6. United kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment Type
15.6.2.2. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment Type
15.7.2.2. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment Type
15.8.2.2. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment Type
15.9.2.2. By End User
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment Type
15.10.2.2. By End User
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment Type
15.11.2.2. By End User
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment Type
15.12.2.2. By End User
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment Type
15.13.2.2. By End User
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment Type
15.14.2.2. By End User
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment Type
15.15.2.2. By End User
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment Type
15.16.2.2. By End User
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment Type
15.17.2.2. By End User
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment Type
15.18.2.2. By End User
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment Type
15.19.2.2. By End User
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment Type
15.20.2.2. By End User
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment Type
15.21.2.2. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment Type
16.3.3. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Nipro Corp.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Fresenius Medical Care AG & Co. KGaA
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Baxter International, Inc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Medtronic Plc
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. B. Braun Melsungen AG
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Asahi Kasei Medical Co., Ltd.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Cantel Medical
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Nikkiso Co., Ltd.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. JMS Co. Ltd.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. AstraZeneca
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Renal Insufficiency Treatment Market
